The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2017 | BCL2 inhibition and CLL: the role of venetoclax
Peter Hillmen, MBChB, PhD, FRCP, FRCPath from Leeds Teaching Hospital NHS trust, Leeds, UK speaks about BCL2 inhibition and venetoclax treatment for patients with chronic lymphocytic leukemia (CLL). In CLL, cells are blocked from undergoing apoptosis, and a BCL2 inhibitor can cause the reversal of this block. An example of a BCL2 inhibitor is venetoclax; after its administration, cells undergo rapid apoptosis to the extent that the patient can develop tumor lysis syndrome (TLS). Thus, it is crucial that venetoclax is administered carefully and strategically. This interview was recorded at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
